Hellström KE - Search Results

1

In situ adenovirus vaccination engages T effector cells against cancer.

Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY, Strauss R, Hellström KE, Disis ML, Roffler S, Lieber A. Tuve S, et al. Among authors: hellstrom ke. Vaccine. 2009 Jun 24;27(31):4225-39. doi: 10.1016/j.vaccine.2009.03.074. Epub 2009 Apr 16. Vaccine. 2009. PMID: 19481312 Free PMC article.

2

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.

Di Paolo NC, Tuve S, Ni S, Hellström KE, Hellström I, Lieber A. Di Paolo NC, et al. Among authors: hellstrom i, hellstrom ke. Cancer Res. 2006 Jan 15;66(2):960-9. doi: 10.1158/0008-5472.CAN-05-2388. Cancer Res. 2006. PMID: 16424031 Free PMC article.

3

Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.

Zhang H, Knutson KL, Hellstrom KE, Disis ML, Hellstrom I. Zhang H, et al. Among authors: hellstrom i, hellstrom ke. Mol Cancer Ther. 2006 Jan;5(1):149-55. doi: 10.1158/1535-7163.MCT-05-0206. Mol Cancer Ther. 2006. PMID: 16432173

4

Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.

Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE, Hellström I. Disis ML, et al. Among authors: hellstrom i, hellstrom ke. Mol Cancer Ther. 2003 Oct;2(10):995-1002. Mol Cancer Ther. 2003. PMID: 14578464

5

Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.

Yang Y, Yang S, Ye Z, Jaffar J, Zhou Y, Cutter E, Lieber A, Hellström I, Hellström KE. Yang Y, et al. Among authors: hellstrom i, hellstrom ke. Cancer Res. 2007 Mar 1;67(5):2339-44. doi: 10.1158/0008-5472.CAN-06-3593. Cancer Res. 2007. PMID: 17332366

6

Therapeutic vaccination with tumor cells that engage CD137.

Hellstrom KE, Hellstrom I. Hellstrom KE, et al. Among authors: hellstrom i. J Mol Med (Berl). 2003 Feb;81(2):71-86. doi: 10.1007/s00109-002-0413-8. Epub 2003 Feb 8. J Mol Med (Berl). 2003. PMID: 12601523 Review.

7

Novel approaches to therapeutic cancer vaccines.

Hellstrom KE, Hellstrom I. Hellstrom KE, et al. Among authors: hellstrom i. Expert Rev Vaccines. 2003 Aug;2(4):517-32. doi: 10.1586/14760584.2.4.517. Expert Rev Vaccines. 2003. PMID: 14711336 Review.

8

Inhibition of TGFbeta1 makes nonimmunogenic tumor cells effective for therapeutic vaccination.

Liu P, Jaffar J, Zhou Y, Yang Y, Hellström I, Hellström KE. Liu P, et al. Among authors: hellstrom i, hellstrom ke. J Immunother. 2009 Apr;32(3):232-9. doi: 10.1097/CJI.0b013e318197ac86. J Immunother. 2009. PMID: 19242377

9

Costimulation of T cells for tumor immunity.

Chen L, Linsley PS, Hellström KE. Chen L, et al. Among authors: hellstrom ke. Immunol Today. 1993 Oct;14(10):483-6. doi: 10.1016/0167-5699(93)90262-J. Immunol Today. 1993. PMID: 7506034 Review.

10

Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.

Yang S, Yang Y, Raycraft J, Zhang H, Kanan S, Guo Y, Ronai Z, Hellstrom I, Hellstrom KE. Yang S, et al. Among authors: hellstrom i, hellstrom ke. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4990-5. doi: 10.1073/pnas.0400880101. Epub 2004 Mar 29. Proc Natl Acad Sci U S A. 2004. PMID: 15051893 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

380 results

Search Page